Girard Partners LTD Has Boosted Constellation Brands (STZ) Position; Techne (TECH) Has 1.32 Sentiment

June 21, 2018 - By Winifred Garcia

Bio-Techne Corporation (NASDAQ:TECH) Logo

Girard Partners Ltd increased Constellation Brands Inc (STZ) stake by 28.84% reported in 2018Q1 SEC filing. Girard Partners Ltd acquired 3,344 shares as Constellation Brands Inc (STZ)’s stock declined 0.56%. The Girard Partners Ltd holds 14,940 shares with $3.41M value, up from 11,596 last quarter. Constellation Brands Inc now has $43.93B valuation. The stock decreased 0.40% or $0.91 during the last trading session, reaching $230.59. About 352,024 shares traded. Constellation Brands, Inc. (NYSE:STZ) has risen 20.36% since June 21, 2017 and is uptrending. It has outperformed by 7.79% the S&P500. Some Historical STZ News: 20/03/2018 – CONSTELLATION TO INVEST $900M IN MEXICO PLANT TO BOOST OUTPUT; 30/05/2018 – Constellation Names Chicago Charities to Receive Donations as Part of 2018 Constellation SENIOR PLAYERS Championship; 15/03/2018 – 2Checkout Named to Constellation ShortLists™ for Digital Monetization and Campaign to Commerce; 22/04/2018 – DJ Constellation Brands Inc Class A, Inst Holders, 1Q 2018 (STZ); 29/03/2018 – STZ CEO: MODELO ESPECIAL NOW NO.1 BEER IN CALIFORNIA; 29/03/2018 – CONSTELLATION BRANDS INC – QTRLY COMPARABLE EPS $1.90; 29/03/2018 – Corona maker Constellation Brands’s quarterly sales top estimates; 29/03/2018 – STZ CEO: TESTING SVEDKA SPIKED SELTZERS IN SUMMER 2018; 27/03/2018 – NVIDIA Introduces DRIVE Constellation Simulation System to Safely Drive Autonomous Vehicles Billions of Miles in Virtual Reality; 06/03/2018 – PROS Earns Placement on Constellation ShortList™ for Price Optimization Solutions




Techne Corp (TECH) investors sentiment increased to 1.32 in 2018 Q1. It’s up 0.34, from 0.98 in 2017Q4. The ratio is positive, as 136 funds increased and opened new equity positions, while 103 trimmed and sold holdings in Techne Corp. The funds in our database now have: 35.01 million shares, down from 35.53 million shares in 2017Q4. Also, the number of funds holding Techne Corp in top ten equity positions increased from 2 to 4 for an increase of 2. Sold All: 14 Reduced: 89 Increased: 83 New Position: 53.

Since January 30, 2018, it had 0 insider purchases, and 4 selling transactions for $6.69 million activity. 6,398 shares were sold by LOCKE JAMES A III, worth $1.47M on Tuesday, April 17. FROMBERG BARRY A sold $687,672 worth of stock. Klein David Eric had sold 17,900 shares worth $4.09M on Monday, April 2.

Among 23 analysts covering Constellation Brands (NYSE:STZ), 15 have Buy rating, 0 Sell and 8 Hold. Therefore 65% are positive. Constellation Brands had 84 analyst reports since August 27, 2015 according to SRatingsIntel. The company was maintained on Friday, December 22 by Stifel Nicolaus. The stock of Constellation Brands, Inc. (NYSE:STZ) earned “Outperform” rating by Wells Fargo on Tuesday, April 5. The stock of Constellation Brands, Inc. (NYSE:STZ) earned “Overweight” rating by Barclays Capital on Thursday, April 7. The firm has “Outperform” rating by RBC Capital Markets given on Wednesday, December 16. The rating was maintained by Morgan Stanley on Monday, July 10 with “Buy”. BMO Capital Markets initiated it with “Buy” rating and $275.0 target in Monday, February 5 report. Credit Suisse maintained the stock with “Hold” rating in Thursday, June 29 report. On Thursday, September 17 the stock rating was initiated by Nomura with “Neutral”. The stock of Constellation Brands, Inc. (NYSE:STZ) earned “Outperform” rating by Cowen & Co on Monday, November 23. The rating was maintained by Pivotal Research on Thursday, June 29 with “Buy”.

Girard Partners Ltd decreased Vanguard Bd Index Fd Inc Intermed Term (BIV) stake by 33,312 shares to 22,313 valued at $1.83M in 2018Q1. It also reduced Ishares Tr Core Us Aggbd Et (AGG) stake by 7,513 shares and now owns 24,658 shares. Ishares Tr Us Hlthcare (IYH) was reduced too.

Investors sentiment decreased to 1.18 in 2018 Q1. Its down 0.06, from 1.24 in 2017Q4. It fall, as 45 investors sold STZ shares while 256 reduced holdings. 99 funds opened positions while 256 raised stakes. 134.88 million shares or 3.87% less from 140.30 million shares in 2017Q4 were reported. Hap Trading Lc has 0.79% invested in Constellation Brands, Inc. (NYSE:STZ). Norinchukin Bancshares The, a Japan-based fund reported 15,705 shares. Williams Jones And Ltd Liability Co, New York-based fund reported 26,344 shares. Highbridge Capital Mgmt Ltd Liability stated it has 0.02% in Constellation Brands, Inc. (NYSE:STZ). Scholtz Co Limited stated it has 2.94% of its portfolio in Constellation Brands, Inc. (NYSE:STZ). First Foundation Advsrs stated it has 0.01% in Constellation Brands, Inc. (NYSE:STZ). Goldman Sachs Gp has 1.62M shares for 0.09% of their portfolio. Zeke Cap Ltd reported 3,796 shares. Melvin LP accumulated 2.35M shares or 5.11% of the stock. Cibc Ww Mkts reported 0.2% of its portfolio in Constellation Brands, Inc. (NYSE:STZ). Caisse De Depot Et Placement Du Quebec owns 19,085 shares for 0.01% of their portfolio. Amundi Pioneer Asset Inc invested in 212,119 shares or 0.08% of the stock. Archford Cap Strategies Llc has 28 shares for 0% of their portfolio. Connecticut-based Impala Asset Management has invested 0.21% in Constellation Brands, Inc. (NYSE:STZ). 3G Ptnrs Lp reported 263,066 shares.

More notable recent Constellation Brands, Inc. (NYSE:STZ) news were published by: Fool.com which released: “Constellation Brands Has a Secret Weapon in the Beer Wars: Trump’s Tariffs” on June 16, 2018, also Fool.com with their article: “This Is the Real Reason to Love Constellation Brands Stock” published on June 02, 2018, Seekingalpha.com published: “Buy Lockheed Martin On Weakness – Cramer’s Lightning Round (6/14/18)” on June 15, 2018. More interesting news about Constellation Brands, Inc. (NYSE:STZ) were released by: Fool.com and their article: “3 Reasons Constellation Brands’ Stock Could Rise” published on June 07, 2018 as well as Fool.com‘s news article titled: “3 Top Stocks That Are Cash Cows” with publication date: June 16, 2018.

Ratings analysis reveals 100% of Bio-Techne’s analysts are positive. Out of 2 Wall Street analysts rating Bio-Techne, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $115.0 while the high is $115.0. The stock’s average target of $115 is -28.65% below today’s ($161.18) share price. TECH was included in 2 notes of analysts from January 18, 2017. Deutsche Bank initiated Bio-Techne Corporation (NASDAQ:TECH) rating on Wednesday, January 18. Deutsche Bank has “Buy” rating and $115.0 target. Citigroup initiated the stock with “Buy” rating in Thursday, February 9 report.

Since January 1, 0001, it had 0 buys, and 3 sales for $2.13 million activity.

Sandhill Capital Partners Llc holds 3.74% of its portfolio in Bio-Techne Corporation for 150,946 shares. Brown Capital Management Llc owns 1.99 million shares or 3.41% of their US portfolio. Moreover, Summit Creek Advisors Llc has 3.28% invested in the company for 119,419 shares. The New York-based Stone Run Capital Llc has invested 2.96% in the stock. Mairs & Power Inc, a Minnesota-based fund reported 1.38 million shares.

Bio-Techne Corporation, together with its subsidiaries, develops, makes, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. The company has market cap of $6.06 billion. It operates through three divisions: Biotechnology, Protein Platforms, and Diagnostics. It has a 54.45 P/E ratio. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.

The stock decreased 1.12% or $1.82 during the last trading session, reaching $161.18. About 36,121 shares traded. Bio-Techne Corporation (TECH) has risen 33.83% since June 21, 2017 and is uptrending. It has outperformed by 21.26% the S&P500. Some Historical TECH News: 26/04/2018 – Bio-Techne Leads the Way in Scientific Support for Autophagy Research; 24/04/2018 – Bio-Techne Names Kim Kelderman as Pres, Diagnostics and Genomics; 22/04/2018 – DJ Bio-Techne Corporation, Inst Holders, 1Q 2018 (TECH); 02/05/2018 – BIO-TECHNE 3Q ADJ EPS $1.21, EST. $1.14; 02/05/2018 – Bio-Techne 3Q EPS 52c; 24/04/2018 – Bio-Techne Announces New Leadership Appointment; 14/03/2018 – Bio-Techne Launches MimEX™ Gl, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal Tract; 10/04/2018 – Bio-Techne at Deutsche Bank Health Care Conference May 8; 10/05/2018 – Bio-Techne at UBS Global Health Care Conference May 22; 14/03/2018 Bio-Techne Launches MimEX™ GI, an Accessible 3-D Cell Culturing Platform for the Gastrointestinal Tract

Analysts await Bio-Techne Corporation (NASDAQ:TECH) to report earnings on August, 14. They expect $1.18 earnings per share, up 15.69% or $0.16 from last year’s $1.02 per share. TECH’s profit will be $44.34M for 34.15 P/E if the $1.18 EPS becomes a reality. After $1.13 actual earnings per share reported by Bio-Techne Corporation for the previous quarter, Wall Street now forecasts 4.42% EPS growth.

Constellation Brands, Inc. (NYSE:STZ) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.